On December $22,2022,$ the Company acquired Abiomed, a leading provider of cardiovascular medical technology, for $$17\mathrm{.}1$ billion cash. $[$from Note $18]$ "The fair value of the acquisition was allocated to assets acquired of $$11\mathrm{.}5$ billion and liabilities assumed of $$2\mathrm{.}8$ billion, which includes the fair value of the contingent

$1|$ Page $|$

consideration mentioned above fos $$0\mathrm{.}7$ billion and deferred taxes of $$1\mathrm{.}8$ billion." Prepare the journal entry to record the transaction.

What effect, if any, will the excess of cash over identifiable net assets acquired in this acquisition have on Johnson & Johnson's earnings in future years?